Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Saved in:
| Title: | Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. |
|---|---|
| Authors: | Li Y; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Amaladas N; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., O'Mahony M; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America., Inigo I; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Li Q; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Rasmussen ER; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Brahmachary M; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Doman TN; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America., Hall G; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Kalos M; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Novosiadly R; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America., Puig O; Lilly Oncology, Alexandria Center for Life Sciences, New York City, New York, United States of America., Pytowski B; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America., Schaer DA; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America. |
| Source: | PloS one [PLoS One] 2022 Jul 18; Vol. 17 (7), pp. e0268244. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
